Cargando…

A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females

BACKGROUND: Erenumab is a human anti-calcitonin gene-related peptide monoclonal antibody developed for migraine prevention. Migraine predominately affects women of childbearing age; thus, it is important to determine potential drug–drug interactions between a common oral contraceptive and drugs used...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yang, Gabriel, Kristin, Wang, Yi, Zhou, Yanchen, Eisele, Osaro, Vutikullird, Apinya, Mikol, Daniel D., Lee, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520319/ https://www.ncbi.nlm.nih.gov/pubmed/30963506 http://dx.doi.org/10.1007/s40263-019-00626-2

Ejemplares similares

A Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
por: Depre, Christophe, et al.
Publicado: (2018)

Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies
por: Meier, Edward, et al.
Publicado: (2017)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Erenumab for headaches in idiopathic intracranial hypertension: A prospective open‐label evaluation
por: Yiangou, Andreas, et al.
Publicado: (2020)

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
por: Ashina, Messoud, et al.
Publicado: (2019)

Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects
por: Vu, Thuy, et al.
Publicado: (2017)

Efficacy and safety of erenumab in women with a history of menstrual migraine
por: Pavlovic, Jelena M., et al.
Publicado: (2020)

Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial
por: Kothare, Prajakti A, et al.
Publicado: (2012)

Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
por: de Hoon, Jan, et al.
Publicado: (2018)

Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers
por: Menon, Sujatha, et al.
Publicado: (2016)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
por: Sakai, Fumihiko, et al.
Publicado: (2019)

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial
por: Tepper, Stewart J., et al.
Publicado: (2019)

One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study
por: Lipton, Richard B., et al.
Publicado: (2019)

Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
por: De Icco, Roberto, et al.
Publicado: (2022)

Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
por: Sara, Bottiroli, et al.
Publicado: (2021)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

An Open‐Label Study to Evaluate the Effect of Eluxadoline on the Single‐Dose Pharmacokinetics of Midazolam in Healthy Participants
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies
por: Hirata, Koichi, et al.
Publicado: (2022)

Effect of Prucalopride on the Pharmacokinetics of Oral Contraceptives in Healthy Women
por: Van de Velde, Vera, et al.
Publicado: (2013)

The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
por: Broessner, Gregor, et al.
Publicado: (2020)

Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
por: Bottiroli, Sara, et al.
Publicado: (2021)

Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study
por: Yu, Qi, et al.
Publicado: (2018)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study
por: Cong, Duanduan, et al.
Publicado: (2022)

Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
por: Acharya, M., et al.
Publicado: (2012)

Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022)

Lichenoid drug eruption induced by erenumab
por: Musicante, Meryl, et al.
Publicado: (2022)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study
por: Ashina, Håkan, et al.
Publicado: (2020)

An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch
por: Zhang, Chao, et al.
Publicado: (2017)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial
por: Hirata, Koichi, et al.
Publicado: (2023)

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study
por: Takeshima, Takao, et al.
Publicado: (2021)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single‐center, open‐label phase I trial
por: Deng, Kunhong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7glsdi3msmjqaa4chr7aa5q30h